Case-control analysis identifies lipid metabolism biomarkers for ischemic stroke, suggesting new diagnostic approaches.
Ischemic stroke (IS) accounts for over 80% of all stroke cases, presenting as a prevalent, debilitating cerebrovascular disorder with limited therapeutic options. The urgent need for early diagnostic biomarkers and insights into pathogenesis has highlighted dysregulated lipid metabolism as a key contributor, while metabolomics advances enable novel biomarker exploration. This study integrated bioinformatics and a case-control design to investigate IS-related lipid metabolism pathways and blood lipid biomarkers. Gene Expression Omnibus (GEO) gene expression datasets were analyzed via Gene Set Enrichment Analysis (GSEA) to identify lipid pathways, and case-control analyses employed Chi-square/Z tests for conventional blood lipids, Liquid Chromatography-Mass Spectrometry (LC-MS) for plasma small-molecule lipids, and orthogonal partial least squares discriminant analysis, t-tests, and Receiver Operating Characteristic (ROC) curves for validation. Results revealed five significantly downregulated lipid pathways (α-linolenic acid, linolenic acid, ether lipid, glycerophospholipid, and sphingolipid metabolism). IS patients exhibited dyslipidemia (elevated TC/TG/LDL-C, reduced HDL-C). Additionally, 15 differentially expressed lipid molecules were identified in a validation cohort after excluding the influence of comorbidities. Among these, five representative lipids (e.g., PE(P-18:1/22:4)) demonstrated potential diagnostic performance, with an area under the receiver operating characteristic curve (AUC) of 0.917, sensitivity of 60.0%, and specificity of 96.7%, indicating their potential utility as biomarkers for the early detection of IS.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: